Skip to main content
. Author manuscript; available in PMC: 2016 Jul 6.
Published in final edited form as: Invest New Drugs. 2014 Nov 23;33(1):86–94. doi: 10.1007/s10637-014-0185-3

Figure 6. Possible involvement of the Glycogen Synthase Kinase 3 beta pathway in NFκB inhibition by microsclerodermin A.

Figure 6

Graphical representation of the flow cytometry data for intracellular staining of AsPC-1 cells treated for 6 hours with 2.4μM microsclerodermin A or vehicle control. Data shown is the average of 3 experiments, error bars represent standard error of the mean. The levels of phosphorylated (inactive) GSK3β, phosphorylated AKT and phosphorylated cyclin D1 are increased by treatment of AsPC-1 cells with microsclerodermin A. These increases suggest that microsclerodermin A may inhibit NFκB through inactivation of the GSK3β signaling pathway. However, none of these increases was statistically significant using a student’s T test.